이는 작년 총 27개의 신약이 승인받은 것을 고려할 때, 2014년도 제약 시장이 좀 더 활기를 띨 것으로 보입니다. 다만, 작년 상반기에는 30% 이상 차지했던 항암 신약이, 2014년 상반기에는 20% 미만으로 나타났습니다.
|
|
Drug (brand name)
|
Lead company
|
Indication
|
|
1
|
Dapagliflozin (Farxiga)
|
AstraZeneca
|
Type 2 diabetes
|
|
2
|
Tasimelteon (Hetlioz)
|
Vanda
|
Non-24-hour sleep–wake disorder
|
|
3
|
Elosulfase alfa (Vimizim)*
|
Biomarin
|
Mucopolysaccharidosis type IVA
|
|
4
|
Droxidopa (Northera)
|
Chelsea Therapeutics
|
Neurogenic orthostatic hypotension
|
|
5
|
Metreleptin (Myalept)*
|
Amylin
|
Leptin deficiency in patients with congenital or acquired generalized lipodystrophy
|
|
6
|
Florbetaben F‑18 (Neuraceq)
|
Piramal
|
Imaging of the brain to estimate β-amyloid neuritic plaque density
|
|
7
|
Miltefosine (Impavido)
|
Paladin
|
Leishmania donovani, Leishmania braziliensis, Leishmania guyanensis or Leishmania panamensis infection
|
|
8
|
Apremilast (Otezla)
|
Celgene
|
Psoriatic arthritis
|
|
9
|
Albiglutide (Tanzeum)*
|
GlaxoSmithKline
|
Type 2 diabetes
|
|
10
|
Ramucirumab (Cyramza)*
|
Eli Lilly
|
Gastric cancer
|
|
11
|
Siltuximab (Sylvant)*
|
Janssen
|
Multicentric Castleman’s disease
|
|
12
|
Ceritinib (Zykadia)
|
Novartis
|
Anaplastic lymphoma kinase (ALK)-positive metastatic non-small-cell lung cancer
|
|
13
|
Vorapaxar (Zontivity)
|
Merck & Co.
|
Thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease
|
|
14
|
Vedolizumab (Entyvio)*
|
Takeda
|
Ulcerative colitis and Crohn’s disease
|
|
15
|
Dalbavancin (Dalvance)
|
Durata
|
ABSSSI caused by designated susceptible Gram-positive microorganisms
|
|
16
|
Efinaconazole (Jublia)
|
Dow Pharmaceuticals
|
Onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophyte
|
|
17
|
Tedizolid (Sivextro)
|
Cubist
|
ABSSSI caused by designated susceptible Gram-positive microorganisms
|
* BLA
